Embecta Corp./$EMBC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
- Ticker
- $EMBC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,850
- Headquarters
- Parsippany, United States
- Website
- www.embecta.com
Embecta Corp. Metrics
BasicAdvanced
$354M
4.25
$1.47
0.85
$0.32
0.64%
Price and volume
Market cap
$354M
Beta
0.85
52-week high
$14.91
52-week low
$2.77
Average daily volume
906K
Dividend rate
$0.32
Financial strength
Current ratio
1.68
Quick ratio
0.945
Long term debt to equity
-2.192
Total debt to equity
-2.451
Dividend payout ratio (TTM)
31.09%
Interest coverage (TTM)
2.36%
Profitability
EBITDA (TTM)
281.5
Gross margin (TTM)
58.42%
Net profit margin (TTM)
8.59%
Operating margin (TTM)
23.29%
Effective tax rate (TTM)
30.00%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
12.24%
Return on equity (TTM)
-13.65%
Valuation
Price to earnings (TTM)
4.253
Price to revenue (TTM)
0.361
Price to book
-0.58
Price to tangible book (TTM)
-0.51
Price to free cash flow (TTM)
2.232
Free cash flow yield (TTM)
44.81%
Free cash flow per share (TTM)
2.801
Dividend yield (TTM)
5.12%
Forward dividend yield
0.64%
Growth
Revenue change (TTM)
-7.60%
Earnings per share change (TTM)
3.42%
3-year revenue growth (CAGR)
-2.92%
3-year earnings per share growth (CAGR)
21.14%
3-year dividend per share growth (CAGR)
-8.48%
What the Analysts think about Embecta Corp.
Analyst ratings (Buy, Hold, Sell) for Embecta Corp. stock.
Analyst projections of the future price of Embecta Corp. stock.
Bulls say / Bears say
After a difficult first half, Embecta reported a marked sequential improvement in the third quarter and raised its 2026 adjusted EPS outlook to $1.80–$1.90. The higher forecast suggests cost and operating improvements may be helping earnings, although revenue is still expected to fall. (SEC, MarketWatch)
The Owen Mumford acquisition adds auto-injectors and other medical devices, expanding Embecta beyond its declining insulin-injection business. Embecta plans to use its global sales network to grow these products and its pharmaceutical-services business. (GlobeNewswire)
Embecta has already secured real-world placements for its pen needles in generic GLP-1 products, with launches reported in India, Canada and Brazil. If these partnerships scale, they could open a new sales channel alongside traditional diabetes-care products. (SEC)
The core US business remains under pressure: third-quarter US revenue fell 24.6%, while pen-needle revenue declined 18.2%. The company attributed the wider sales fall to lower prices and volumes, leaving a substantial recovery challenge. (SEC)
Profitability has weakened sharply: nine-month adjusted gross margin fell to 60.1% from 64.6%, and adjusted EPS dropped to $1.53 from $2.46. The raised full-year EPS forecast does not change the outlook for a steep decline in organic constant-currency revenue. (SEC)
Embecta had about $1.47bn of debt against $218m of cash and restricted cash at June 2026, and paid $56.3m in interest in the first nine months of the year. That debt load limits financial flexibility while the business is shrinking and the company integrates its acquisition. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
Embecta Corp. Financial Performance
Revenues and expenses
Embecta Corp. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Embecta Corp. News
AllArticlesVideos
EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Newsfile Corp2 months ago
EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Newsfile Corp3 months ago
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Business Wire3 months ago
Funds containing Embecta Corp.
Fund name | Fund size | $EMBC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.